Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

Related Keywords

Zurich , Züsz , Switzerland , Frankfurt , Brandenburg , Germany , Swiss , Stig Hansen , Thomas Schinecker , Sharon Singleton , Roche Graham , Eli Lilly , Teresa Graham , Zuercher Kantonalbank , Ludwig Burger , Lilly Mounjaro , Noel Illien , Astrazeneca , Pfizer , Novo Nordisk , Reuters , Carmot Therapeutics , Kimia Therapeutics , Frankfurt Additional , Rachel More , Louise Heavens , Weight Management , Obesity , Bese , Glp 1 Receptor Agonists , Glucagon Like Peptide 1 Receptor Agonists , Weight Loss , Drug Development , Drug Discovery , Drug Pipeline , Drug Development Pipeline ,